Market access focus Cogentia positions itself as a leading market access consultancy for pharmaceutical and healthcare products, offering services from early discovery potential to pricing adjustments for mature products. This suggests opportunities to upsell pricing strategy, market access research, payer engagement, and policy/regulatory support for companies seeking faster market entry and sustained uptake.

Global reach Although based in Cambridge, Cogentia handles projects across all major therapeutic areas and markets worldwide. Sales opportunities exist with global pharma, biotech, device, and diagnostic firms seeking consistent market access guidance across regions, including emerging markets where payer landscapes are evolving.

Diverse client base Their client mix includes established companies, biotechs, startups, and investors, indicating potential for scalable service bundles from early feasibility to lifecycle management. Targeted offerings for venture-backed firms and portfolio companies can address funding rounds, product prioritization, and exit strategies.

Tech-enabled insights Cogentia employs a modern tech stack including OpenAI, Google Cloud, and data-driven research capabilities, which can be leveraged to offer scalable market access analytics, synthetic data modeling for pricing scenarios, and competitive intelligence to prospective clients seeking data-backed decisions.

Recent exit signal Recent news of a sale arbitration with Alfa Corporate Finance and Helios Global Group indicates exit or strategic partnership activity in their client ecosystem. This may present cross-sell opportunities for advisory services related to transaction support, due diligence, and integration planning for buyers or sellers in the life sciences space.